Was wondering if there was anything in the news that might explain GH being down 7% vs other stocks in my portfolio (ZS, AYX, MDB, TWLO, etc) being down (if at all) in the 1-3% range. Did I miss something?
Another biotech I am tracking (QTNT) is also down > 7%.
Was wondering if there was anything in the news that might explain GH being down 7% vs other stocks in my portfolio being down (if at all) in the 1-3% range.
Hi kmart,
You must be kidding, right? How about Gardant being up over 80%, from $40 to $70, in the previous three weeks? And then you are complaining about a 7% pullback? In the midst of a general market pullback?
Saul
Sorry, I meant 75% to $70. It was up over 82% to the intraday high of $73.
And then you are complaining about a 7% pullback? In the midst of a general market pullback?
Hi Saul,
I don’t think he was complaining, he was just asking a question.
Kmart, as Saul said, this is most likely just a pullback from GH being up so much over the last month. Completely normal. There hasn’t been any news today about Gaurdant.
CloudAtlas
Actually, I’ve been building my position on the dips. I’m really impressed with their research team.
CloudAtlas is correct, I was just wondering why GH is down today-- I assumed it was pulling back from the pop last week, but wanted to make sure I didnt miss something.
I also picked up more shares recently–this, ZS and AYX are my high conviction stocks.
Having re-read my initial post, I realize now that it seemed that I was down 7% on GH…
I got in recently, but I am overall enjoying a gain of about 14% on my initial purchase… My subsequent purchase is down a bit, but that was picked up Monday/not too concerned.
Was wondering if there was anything in the news that might explain GH being down 7% vs other stocks in my portfolio (ZS, AYX, MDB, TWLO, etc) being down (if at all) in the 1-3% range. Did I miss something?
Another biotech I am tracking (QTNT) is also down > 7%.
I believe that there is a sector-wide sell-off in biotechs/drugs as a result of the FDA Commissioner’s abrupt resignation. He was seen as a champion of more efficiency and responsiveness from the agency, not that I see Trump appointing someone else who won’t be industry-friendly.
Biotech ETF’s were down 4.1% and 3.1%. I remembered, but could not find, some news again that biotech feared regulatory pressures on pricing.
KC
Kmart (and others), Sometimes I use StockTwits to run an instant check on news for a specific company. Just put in the symbol and you’ll get an instant feed of news, rumors, TA, etc. Have to wade through strong bull and bear posts and sometimes irrelevant comments but often breaking news shows up there even when can’t find any news via Google search, etc.
David
Biotech ETF’s were down 4.1% and 3.1%. I remembered, but could not find, some news again that biotech feared regulatory pressures on pricing.
Could it be related to FDA commissioner Scott Gottlieb resigning?
Biotech ETF’s were down 4.1% and 3.1%. I remembered, but could not find, some news again that biotech feared regulatory pressures on pricing. Could it be related to FDA commissioner Scott Gottlieb resigning?
That’s a good point LGM, as he was apparently devoted to streamlining the FDA approval process, which would be very relevant to the early stage biotechs that some of us may be following.
Saul